Literature DB >> 22294989

Access to cancer drugs in Canada: looking beyond coverage decisions.

Roger Chafe1, Anthony Culyer, Mark Dobrow, Peter C Coyte, Carol Sawka, Susan O'Reilly, Kara Laing, Maureen Trudeau, Sharon Smith, Jeffrey S Hoch, Steve Morgan, Stuart Peacock, Rick Abbott, Terrence Sullivan.   

Abstract

OBJECTIVE: To examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs. DATA SOURCES/STUDY
DESIGN: We surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs. PRINCIPAL
FINDINGS: While there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs.
CONCLUSIONS: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.

Entities:  

Year:  2011        PMID: 22294989      PMCID: PMC3082385          DOI: 10.12927/hcpol.2011.22177

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  6 in total

1.  Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic).

Authors:  Thomas McGinn; Peter C Wyer; Thomas B Newman; Sheri Keitz; Rosanne Leipzig; Gordon Guyatt For
Journal:  CMAJ       Date:  2004-11-23       Impact factor: 8.262

2.  Access to drugs for cancer: Does where you live matter?

Authors:  Devidas Menon; Tania Stafinski; Gavin Stuart
Journal:  Can J Public Health       Date:  2005 Nov-Dec

Review 3.  Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Authors:  Mike Tierney; Braden Manns
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

4.  The variation phenomenon in 1994.

Authors:  D Blumenthal
Journal:  N Engl J Med       Date:  1994-10-13       Impact factor: 91.245

5.  Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada.

Authors:  S Verma; S Sehdev; A A Joy
Journal:  Curr Oncol       Date:  2007-12       Impact factor: 3.677

6.  The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.

Authors:  Scott R Berry; Stacey Hubay; Hagit Soibelman; Douglas K Martin
Journal:  BMC Health Serv Res       Date:  2007-11-28       Impact factor: 2.655

  6 in total
  10 in total

Review 1.  Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?

Authors:  Devidas Menon; Derek Clark; Tania Stafinski
Journal:  Healthc Policy       Date:  2015-08

2.  Resident-Level Predictors of Dementia Pharmacotherapy at Long-Term Care Admission: The Impact of Different Drug Reimbursement Policies in Ontario and Saskatchewan: Prédicteurs de la pharmacothérapie de la démence au niveau des résidents lors de l'hospitalisation dans des soins de longue durée : l'impact de différentes politiques de remboursement des médicaments en Ontario et en Saskatchewan.

Authors:  Laura C Maclagan; Susan E Bronskill; Michael A Campitelli; Shenzhen Yao; Christoffer Dharma; David B Hogan; Nathan Herrmann; Joseph E Amuah; Colleen J Maxwell
Journal:  Can J Psychiatry       Date:  2020-04-10       Impact factor: 4.356

3.  Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program.

Authors:  M Sorin; E L Franco; A Quesnel-Vallée
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

4.  Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis.

Authors:  Reka Pataky; David A Tran; Andrea Coronado; Riaz Alvi; Darryl Boehm; Dean A Regier; Stuart Peacock
Journal:  CMAJ Open       Date:  2018-07-27

5.  Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges.

Authors:  Dolly Han; Martina Trinkaus; Sophie Hogeveen; Muhammad Mamdani; Scott R Berry; Raymond W Jang; Jeffrey S Hoch; Christine Simmons
Journal:  J Oncol Pract       Date:  2013-01-02       Impact factor: 3.840

6.  Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.

Authors:  Heather McDonald; Cathy Charles; Laurie Elit; Amiram Gafni
Journal:  J Mark Access Health Policy       Date:  2016-07-21

Review 7.  Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

Authors:  Elizabeth M Adkins; Lindsay Nicholson; David Floyd; Mark Ratcliffe; Helene Chevrou-Severac
Journal:  Clinicoecon Outcomes Res       Date:  2017-06-10

8.  Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.

Authors:  N Maniadakis; G Kourlaba; J Shen; A Holtorf
Journal:  BMC Health Serv Res       Date:  2017-05-25       Impact factor: 2.655

9.  Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.

Authors:  Selina K Wong; Lovedeep Gondara; Sharlene Gill
Journal:  Curr Oncol       Date:  2021-11-16       Impact factor: 3.677

10.  The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?

Authors:  W Dominika Wranik; Liesl Gambold; Natasha Hanson; Adrian Levy
Journal:  Int J Health Plann Manage       Date:  2016-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.